IgA nephropathy treatment 25 years on: Can we halt progression? The evidence base

Nephrology Dialysis Transplantation

Volumn 19, Issue 5, 2004, Pages 1041-1046

  Ballardie, Francis W ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Evidence base standards; Evidence based medicine; IgA nephropathy treatment; Trial design

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FISH OIL; GLUCOCORTICOID; IMMUNOGLOBULIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; PREDNISOLONE;

DISEASE COURSE; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEINURIA; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ADRENAL CORTEX HORMONES; CLINICAL TRIALS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FISH OILS; GLOMERULONEPHRITIS, IGA; HUMANS;

EID: 2442432465     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh208     Document Type: Editorial

References (40)

1. Lagrue G, Bernard D, Bariety J, Druet P, Guenel J. Traitement par le chlorambucil et l'azathioprine dans les gloméruloné phrites primitives. Résultats d'une étude contrô lée. J Urol Nephrol 1975; 9: 655-672
2. Ballardie FW. Immunoglobulin A-related nephropathies; pathogenesis and treatment. Adv Ren Med 1992; 21: 183-214
3. Hippocrates. 'First do no harm' (c.470-360 B.C.) Epidemics, book I, section XI/Galen (c.130 203 A.D.)
4. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Ass J 1979; 121: 1193-1254
5. Sackett DL, Rosenberg WN, Gray JA et al. Evidence based medicine: what it is and what it isn't. Br Med J 1996; 312: 71-72
6. Guyatt GH, Cook OJ, Sackett DL et al. Grades of recommendation for antithrombotic agents. Chest 1998; 114(55): 4415-4445
7. Peto R, Pike MC, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Br J Cancer 1977; 35: 1-39
8. de Matteo R, May CN. Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol-induced renal vasodilation in sheep. Am J Physiol 1999; 276: 1125-1131
9. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353: 883-887
10. Pozzi C, Andrulli S, del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomised controlled trial. J Am Soc Nephrol 2004; 15: 157-163
11. Katafuchi R, Ikeda K, Mizumasa T et al. Controlled prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis 2003; 41: 972-983
12. Lai KN, Lai FM, Ho CP, Chan KW. Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol 1986; 26: 174-180
13. Kobayashi Y, Fujii K, Hiki Y, Tateno S, Kurokawa A, Kamiyama M. Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron 1988; 48: 12-17
14. Julian BA, Barker C. Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomised, controlled trial. Contrib Nephrol 1993; 104: 198-206
15. Nojima Y, Naruse T. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 2001; 55: 192-195
16. Kobayashi Y, Hiki Y, Kokubo T, Horii A, Tateno S. Steroid therapy during the early stage of progressive IgA nephropathy. Nephron 1996; 72: 237-242
17. Shoji T, Nakanashi I, Suzuki A et al. Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy Am J Kidney Dis 2001; 194-201
18. Schena FP, Strippoli G, Manno C. Therapeutic aspects of IgA nephropathy: an overview. Nephrology 2002; 7: 156-163
19. Tsuruya K, Harada A, Hirakata H et al. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy. Clin Nephrol 2000; 53: 1-9
20. Yoshikawa N, Ito H, Sakai T et al. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol 1999; 10: 101-109
21. Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone with cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 2002; 13: 142-148
22. Rocatello D, Michela F, Giulio C et al. Nephrol Dial Transplant 2000; 15: 833-835
23. Rasche FM, Klotz CH, Czock D et al. Cyclophosphamide pulse therapy in advanced progressive IgA nephropathy. Nephron Clin Pract 2003; 93: 131-136
24. Chen X, Chen P, Cai G et al. A randomised controlled trial of mofetil mycophenolate in severe IgA nephropathy. Zhonga Yi Xue Za Zhi 2002; 82: 796-801
25. Maes BD, Evenepoel P, Kuypers D, Messiaen T, Vanrenterghem Y. A prospective placebo-controlled randomised single centre study of mycophenolate mofetil treatment for IgA nephropathy: lack of clinical efficacy after two years. J Am Soc Nephrol 2001; 12: 114
26. Woo KT, Lee GS, Lau YK, Chiang GS, Lim CH. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol 1991; 36: 60-66
27. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 1990; 34: 103-107
28. Furuta T, Hotta O, Horigome I et al. Steroid pulse therapy combined with tonsillectomy in IgA nephropathy associated with diabetes mellitus. Nephron 2001; 89: 398-401
29. Hotta O, Furuta T, Chiba S. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis 2002; 39: 493-502
30. Xie Y, Nishi Y, Ueno M et al. The efficacy of tonsillectomy on long-term renal survival in patients with IgA nephropathy. Kidney Int 2003; 63: 1861-1867
31. Praga M, Gutiérrez E, González E, Morales E, Hernández E. Treatment of IgA nephropathy with ACE inhibitors: a randomised and controlled trial. J Am Soc Nephrol 2003; 14: 1578-1583
32. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361; 117-124
33. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997; 8: 1739-1744
34. Hogg RJ, Lee J Nordelli NA, Cattren D, Hurschma G, Juliun BA. Multicentre placebo - controlled trial of alternate-day predrisone or daily omega-3 fatty acids in children and young adults with IgA nephropathy. J Am Soc Nephrol 2003; 14: 751A
35. Floege J. Evidence-based recommendations for immunosuppression in IgA nephropathy: handle with caution. Nephrol Dial Transplant 2003: 18: 241-245
36. Ballardie FW. Systemic Lupus and Other Connective Tissue Disease Nephropathies. In Nephrology 1997. Ch51; 306-421. Ed. R Wilkinson and R Jamison, pub. Chapman and Hall, London
37. Kelley VR, Wuthrich RP. Cytokines in the pathogenesis of systemic lupus erythematosus. Semin Nephrol 1999; 19: 57-66
38. deCaestecker M, Bottomley M, Telfer BA, Hutchinson IVH, Vose BM, Ballardie FW. Detection of abnormal cytokine networks in human IgA nephropathy. Kidney Int. 1993; 44: 1298-1308
39. Bakris G, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661
40. Peterson JC, Adler S, Burkart JM et al., Modification of Diet in Renal Disease Study Group. Blood pressure control, proteinuria, and the progression of renal disease. Ann Int Med 1995; 123: 754-762